{"pmid":32379925,"title":"Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.","text":["Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient.","We read with great interest the publication of Messina et al (1) reporting the first case of SARS-CoV2 infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23(2) .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the << cytokine storm >> triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms (3) .","J Eur Acad Dermatol Venereol","Benhadou, F","Del Marmol, V","32379925"],"abstract":["We read with great interest the publication of Messina et al (1) reporting the first case of SARS-CoV2 infection in a young patient of 32-year-old suffering from psoriasis and psoriatic arthritis treated by Guselkumab, a monoclonal antibody that targets specifically the p19 subunit of Interleukin (IL)-23(2) .The patient contracted the SARS-CoV2 infection after a dinner with some friends but fortunately she developed very discrete symptoms including only mild fever and rhinorrhea. These findings support the potential role of IL-23p19 inhibitors to counteract the << cytokine storm >> triggered by the SARS-CoV2 and which is potentially implicated in the severity of the symptoms (3) ."],"journal":"J Eur Acad Dermatol Venereol","authors":["Benhadou, F","Del Marmol, V"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379925","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16590","keywords":["covid-19","sars-cov2","biotherapy","guselkumab","psoriasis"],"e_drugs":["guselkumab"],"topics":["Case Report"],"weight":1,"_version_":1666262687702581248,"score":9.490897,"similar":[{"pmid":32306513,"title":"Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.","text":["Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.","Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.","Dermatol Ther","Mugheddu, Cristina","Dell'Antonia, Massimo","Sanna, Silvia","Agosta, Daniele","Atzori, Laura","Rongioletti, Franco","32306513"],"abstract":["Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home."],"journal":"Dermatol Ther","authors":["Mugheddu, Cristina","Dell'Antonia, Massimo","Sanna, Silvia","Agosta, Daniele","Atzori, Laura","Rongioletti, Franco"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306513","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dth.13433","keywords":["covid-19","cornelia de lange syndrome","guselkumab","intellectual disability","psoriasis"],"locations":["Italian","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"weight":0,"_version_":1666138493413228544,"score":233.17493},{"pmid":32358791,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor.","J Eur Acad Dermatol Venereol","Balestri, R","Rech, G","Girardelli, C R","32358791"],"abstract":["we read with great interest the article entitled \"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor\" published by Messina F. and Piaserico S. in the JEADV.(1) This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a psoriatic patient treated with a biologic. Whilst the authors reported an infection that occurred during therapy with an IL-23 inhibitor, we would like to briefly report one that occurred during therapy with an IL-17 inhibitor."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Rech, G","Girardelli, C R"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358791","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16571","keywords":["il17-inhibitor","sars-cov-2; covid-19; psoriasis","ixekizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495318491137,"score":229.41983},{"pmid":32294258,"title":"SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","text":["SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.","Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns.","J Eur Acad Dermatol Venereol","Messina, F","Piaserico, S","32294258"],"abstract":["Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID-19 in this delicate population concerns."],"journal":"J Eur Acad Dermatol Venereol","authors":["Messina, F","Piaserico, S"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294258","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16468","keywords":["sars-cov-2","biologic","covid-19","guselkumab","psoriasis"],"topics":["Case Report"],"weight":1,"_version_":1666138494320246785,"score":146.2486},{"pmid":32330323,"title":"Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","text":["Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.","J Eur Acad Dermatol Venereol","Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S","32330323"],"abstract":["Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients."],"journal":"J Eur Acad Dermatol Venereol","authors":["Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330323","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16527","keywords":["covid-19","atopic dermatitis","dupilumab","interstitial pneumonia"],"e_drugs":["dupilumab"],"topics":["Case Report"],"weight":1,"_version_":1666138494748065792,"score":137.59412},{"pmid":32468230,"pmcid":"PMC7255969","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32468230"],"abstract":["The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468230","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13555-020-00394-8","keywords":["biologics","covid-19","infection","pandemic","psoriasis","sars-cov-2","virus"],"topics":["Case Report"],"weight":1,"_version_":1668420887157669888,"score":129.00453}]}